Impact of China's drug policy will be visible soon, says Jefferies

The first tenders under the new drug program on China's insulin market are expected in late November and early December. The impact of said program is anticipated to be seen around the New Year, and implementation is slated for early 2022, according to the US-based bank Jefferies.

Photo: Tidsvilde Stine/Ritzau Scanpix

China's new drug policy is predicted to have a big impact on Novo Nordisk's insulin sales on the lucrative national market, says the US-based bank Jefferies after a meeting with Novo's Daniel Bohsen, corporate vice president and head of investor relations at the company.

The first tenders in China's volume-based procurement (VBP) program entailing insulin, a program that secures pharmaceutical companies drug volumes agains a fixed, lower prices in the country, are expected to be available in late November and December. The results from the tenders are expected around the New Year, and the implementation will presumably occur in early 2022, Jefferies writes in a statement on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs